Xponance’s Tarsus Pharmaceuticals TARS Stock Holding History

Xponance’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$260K	Buy	4,128 +444	+12%	+$28.4K	﹤0.01%	1491
2026 Q1	$258K	Buy	3,684 +610	+20%	+$42.6K	﹤0.01%	1358
2025 Q4	$252K	Buy	+3,074	New	+$230K	﹤0.01%	1272

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Xponance's TARS Position: Q2 2026 in Review

Xponance increased its Tarsus Pharmaceuticals (TARS) stake by 12% in Q2 2026, buying an estimated $28.4K and bringing the position to 4,128 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Xponance first reported a position in TARS in Q4 2025 and has held it in 3 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Xponance held 4,128 shares of Tarsus Pharmaceuticals worth $260K as of Q2 2026.
Xponance bought 444 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
Tarsus Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1491 holding.
Xponance first reported a position in Tarsus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.